Eli Lilly Management

Management Kriterienprüfungen 2/4

Eli Lilly's CEO ist Dave Ricks , ernannt in Jan 2017, hat eine Amtszeit von 7.42 Jahren. Die jährliche Gesamtvergütung beträgt $26.57M , bestehend aus 6.1% Gehalt und 93.9% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.076% der Aktien des Unternehmens, im Wert von $608.17M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 6 Jahre bzw. 9.5 Jahre.

Wichtige Informationen

Dave Ricks

Geschäftsführender

US$26.6m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	6.1%
Amtszeit als Geschäftsführer	7.7yrs
Eigentum des Geschäftsführers	0.07%
Durchschnittliche Amtszeit des Managements	6yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	8.3yrs

Jüngste Management Updates

Recent updates

Eli Lilly: I Admit Defeat As I Understated Its Growth Prospects (Upgrade)

Sep 20

Eli Lilly (NYSE:LLY) Gains FDA Approval for EBGLYSS, Expands Strategic Alliances for Market Growth

Sep 18

Eli Lilly and Company: The Floodgates To Growth Keep Opening, A Big Win In China

Jul 25

A Look At The Fair Value Of Eli Lilly and Company (NYSE:LLY)

Jul 16

Wall Street Lunch: Merger Monday In All Its Glory

Jul 08

5 Reasons Eli Lilly Just Keeps Rising

Jun 30

Eli Lilly: Throwing Its Weight Around - But, For How Long? (Technical Analysis)

Jun 24

Eli Lilly And Alzheimer's Disease: The Paucity Of Progress

Jun 17

Eli Lilly Continues To Climb As Alzheimer's Drug Gains FDA Approval

Jun 11

These 4 Measures Indicate That Eli Lilly (NYSE:LLY) Is Using Debt Reasonably Well

Jun 10

Eli Lilly's Growth And Challenges: A Cautious Buy

Jun 01

Eli Lilly: Addressing Supply Challenges Should Accelerate Growth

May 26

Eli Lilly: Bloated Stock

May 01

What You Can Learn From Eli Lilly and Company's (NYSE:LLY) P/S

Apr 22

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Dave Ricks im Vergleich zu den Einnahmen von Eli Lilly verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Jun 30 2024	n/a	n/a	US$7b
Mar 31 2024	n/a	n/a	US$6b
Dec 31 2023	US$27m	US$2m	US$5b
Sep 30 2023	n/a	n/a	US$5b
Jun 30 2023	n/a	n/a	US$6b
Mar 31 2023	n/a	n/a	US$6b
Dec 31 2022	US$21m	US$2m	US$6b
Sep 30 2022	n/a	n/a	US$6b
Jun 30 2022	n/a	n/a	US$6b
Mar 31 2022	n/a	n/a	US$6b
Dec 31 2021	US$22m	US$2m	US$6b
Sep 30 2021	n/a	n/a	US$6b
Jun 30 2021	n/a	n/a	US$6b
Mar 31 2021	n/a	n/a	US$6b
Dec 31 2020	US$24m	US$1m	US$6b
Sep 30 2020	n/a	n/a	US$6b
Jun 30 2020	n/a	n/a	US$6b
Mar 31 2020	n/a	n/a	US$6b
Dec 31 2019	US$21m	US$1m	US$5b
Sep 30 2019	n/a	n/a	US$4b
Jun 30 2019	n/a	n/a	US$4b
Mar 31 2019	n/a	n/a	US$3b
Dec 31 2018	US$17m	US$1m	US$3b
Sep 30 2018	n/a	n/a	US$372m
Jun 30 2018	n/a	n/a	-US$166m
Mar 31 2018	n/a	n/a	US$1b
Dec 31 2017	US$16m	US$1m	-US$86m

Vergütung im Vergleich zum Markt: DaveDie Gesamtvergütung ($USD26.57M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD13.21M).

Entschädigung vs. Einkommen: DaveDie Bezüge der Mitarbeiter sind im vergangenen Jahr um mehr als 20 % gestiegen.

Geschäftsführer

Dave Ricks (56 yo)

7.7yrs

Amtszeit

US$26,565,732

Vergütung

Mr. David A. Ricks, also known as Dave, has been a Director of Adobe Inc. since April 12, 2018 and previously served as its Director since June 2017. He served as a Director of Elanco Animal Health Incorpo...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
David Ricks	Chairman	7.7yrs	US$26.57m	0.067% $ 531.2m
Daniel Skovronsky	EVP, Chief Scientific Officer and President of Lilly Research Laboratories & Lilly immunology	6.3yrs	US$11.85m	0.021% $ 169.9m
Anat Hakim	Executive VP	4.6yrs	US$7.01m	0.0034% $ 26.7m
Jacob Van Naarden	Executive VP & President of Loxo	no data	US$4.89m	0.0023% $ 18.0m
Lucas Montarce	Executive VP & CFO	no data	keine Daten	0.0012% $ 9.2m
Donald Zakrowski	Senior VP of Finance & Chief Accounting Officer	11.8yrs	keine Daten	0.00090% $ 7.1m
Diogo Rau	EVP & Chief Information and Digital Officer	3.3yrs	US$5.10m	0.0012% $ 9.7m
Alonzo Weems	EVP of Enterprise Risk Management and Chief Ethics & Compliance Officer	3.3yrs	keine Daten	0.00088% $ 7.0m
Eric Dozier	Executive Vice President of Human Resources & Diversity	1.8yrs	keine Daten	0.00083% $ 6.6m
Jeffrey Simmons	Senior VP & President of Elanco Animal Health	16.7yrs	US$5.38m	keine Daten
W. Moody	SVP of Global Active Pharmaceutical Ingredient	8.1yrs	keine Daten	keine Daten
Anne White	EVP & President of Lilly Neuroscience	6yrs	keine Daten	0.0073% $ 57.5m

6.0yrs

Durchschnittliche Betriebszugehörigkeit

54yo

Durchschnittliches Alter

Erfahrenes Management: LLYDas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (6 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
David Ricks	Chairman	7.7yrs	US$26.57m	0.067% $ 531.2m
Gabrielle Greene-Sulzberger	Independent Director	3.7yrs	US$335.50k	keine Daten
Sidney Taurel	Chairman Emeritus	15.7yrs	US$13.06m	keine Daten
Jon Erik Fyrwald	Independent Director	18.8yrs	US$344.88k	0.000010% $ 79.0k
Ralph Alvarez	Independent Director	15.4yrs	US$336.00k	0.000080% $ 632.3k
William Kaelin	Independent Director	12.3yrs	US$349.15k	keine Daten
Mary Hedley	Independent Director	2.3yrs	US$319.00k	0.000040% $ 316.2k
Juan Luciano	Lead Independent Director	8.6yrs	US$373.00k	keine Daten
Katherine Baicker	Independent Director	12.8yrs	US$336.00k	keine Daten
Jamere Jackson	Independent Director	7.9yrs	US$345.00k	keine Daten
Karen Walker	Independent Director	5.8yrs	US$359.00k	keine Daten
Kimberly Johnson	Independent Director	3.6yrs	US$316.00k	keine Daten

8.3yrs

Durchschnittliche Betriebszugehörigkeit

62.5yo

Durchschnittliches Alter

Erfahrener Vorstand: LLYDie Vorstandsmitglieder gelten als erfahren (9.5 Jahre durchschnittliche Amtszeit).

Eli Lilly Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Eli Lilly and Co. Appoints Lucas Montarce as CFO

Eli Lilly and Company Announces Retirement of Marschall S. Runge as Independent Director, Effective August 31, 2024

Eli Lilly and Company Announces Resignation of Anat Ashkenazi as Chief Financial Officer, Effective July 2024

Insider notifies of intention to sell stock

Eli Lilly and Company Appoints Melissa Seymour as Executive Vice President of Global Quality and Member of the Executive Committee, Effective July 22, 2024

Eli Lilly and Company Announces Retirement of Alonzo Weems, Executive Vice President of Enterprise Risk Management and Chief Ethics and Compliance Officer, Effective December 31, 2024

Recent updates

Eli Lilly: I Admit Defeat As I Understated Its Growth Prospects (Upgrade)

Eli Lilly (NYSE:LLY) Gains FDA Approval for EBGLYSS, Expands Strategic Alliances for Market Growth

FDA Approves Lilly's EBGLYSS (Lebrikizumab-Lbkz) for Adults and Children 12 Years and Older with Moderate-To-Severe Atopic Dermatitis

Eli Lilly and Co. Appoints Lucas Montarce as CFO

Eli Lilly and Company Announces Positive Topline Results from the QWINT-1 and QWINT-3 Phase 3 Clinical Trials Evaluating Once Weekly Insulin Efsitora Alfa

Eli Lilly: Zepbound Price Cuts Have Multiple Positives, Limited Downside

Eli Lilly: Tirzepatide's Winning Streak Continues

Eli Lilly and Company Announces Positive Topline Results from the Surmount-1 Three-Year Study Evaluating the Efficacy and Safety of Tirzepatide

Eli Lilly and Company Announces Retirement of Marschall S. Runge as Independent Director, Effective August 31, 2024

Price target increased by 7.4% to US$989

Eli Lilly and Company (NYSE:LLY) completed the acquisition of Morphic Holding, Inc. (NasdaqGM:MORF) from TAS Partners, LLC, Timothy Springer, Chafen Lu and others.

Consensus EPS estimates increase by 16%

Price target increased by 7.2% to US$987

Eli Lilly Triggers Our Confirmed Buy Signal (Technical Analysis)

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Eli Lilly and Company Raises Earnings Guidance Full-Year 2024

Upcoming dividend of US$1.30 per share

Eli Lilly: I Expect Strong Q2 Earnings, But The Valuation Is Already Optimistic

Eli Lilly and Company to Report Q2, 2024 Results on Aug 08, 2024

Eli Lilly and Company: The Floodgates To Growth Keep Opening, A Big Win In China

A Look At The Fair Value Of Eli Lilly and Company (NYSE:LLY)

Eli Lilly and Company (NYSE:LLY) entered into an agreement and plan of merger to acquire Morphic Holding, Inc. (NasdaqGM:MORF) from TAS Partners, LLC, Timothy Springer, Chafen Lu and others for $3.2 billion.

Wall Street Lunch: Merger Monday In All Its Glory

Eli Lilly and Company(NYSE:LLY) dropped from Russell 1000 Growth-Defensive Index

5 Reasons Eli Lilly Just Keeps Rising

First quarter dividend of US$1.30 announced

Eli Lilly and Company Declares Dividend for the Third Quarter of 2024, Payable on September 10, 2024

Eli Lilly: Throwing Its Weight Around - But, For How Long? (Technical Analysis)

Eli Lilly and Company Announces Detailed Results from the Surmount-OSA Phase 3 Clinical Trials Evaluating Tirzepatide Injection

Eli Lilly And Alzheimer's Disease: The Paucity Of Progress

Eli Lilly Continues To Climb As Alzheimer's Drug Gains FDA Approval

These 4 Measures Indicate That Eli Lilly (NYSE:LLY) Is Using Debt Reasonably Well

Eli Lilly and Company Announces Resignation of Anat Ashkenazi as Chief Financial Officer, Effective July 2024

Insider notifies of intention to sell stock

Eli Lilly and Company Appoints Melissa Seymour as Executive Vice President of Global Quality and Member of the Executive Committee, Effective July 22, 2024

Eli Lilly and Company Announces Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting

Eli Lilly's Growth And Challenges: A Cautious Buy

Eli Lilly: Addressing Supply Challenges Should Accelerate Growth

Eli Lilly and Company Announces Positive Topline Results from the Qwint-2 and Qwint-4 Phase 3 Clinical Trials Evaluating Once-Week Dosing

Eli Lilly and Company Announces Retirement of Alonzo Weems, Executive Vice President of Enterprise Risk Management and Chief Ethics and Compliance Officer, Effective December 31, 2024

First quarter dividend of US$1.30 announced

Eli Lilly and Company Declares Dividend for the Second Quarter of 2024, Payable on June 10, 2024

Consensus EPS estimates increase by 11%

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Eli Lilly: Bloated Stock

Eli Lilly and Company Raises Earnings Guidance for the Year 2024

Eli Lilly and Company Raises Earnings Guidance for the Year 2024

What You Can Learn From Eli Lilly and Company's (NYSE:LLY) P/S

Eli Lilly and Company to Report Q1, 2024 Results on Apr 30, 2024

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter